Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 5c; Issues Light Q4 Proft Outlook
Tweet Send to a Friend
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.12, $0.05 better than the analyst estimate of $0.07. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
